Financials

	2022	2023
Net sales	4.85Cr 4.18Cr 3.92Cr 3.57Cr 6.73Cr 463.17Cr 6.75Cr 46Cr 18Cr 233.81Cr 18Cr 18Cr 775.26Cr	4.92Cr 4.24Cr 3.97Cr 3.63Cr 6.83Cr 469.88Cr 6.85Cr 47Cr 18Cr 237.19Cr 18Cr 18Cr 786.49Cr
Net income	-2.86Cr -2.47Cr -2.31Cr -2.11Cr -3.98Cr -273.67Cr -3.99Cr -27Cr -11Cr -138.15Cr -11Cr -11Cr -458.07Cr	-2.06Cr -1.78Cr -1.67Cr -1.52Cr -2.87Cr -197.19Cr -2.88Cr -20Cr -7.72Cr -100Cr -7.75Cr -7.58Cr -330.06Cr
Net Debt	1.15Cr 99.16L 92.97L 84.87L 1.6Cr 109.98Cr 1.6Cr 11Cr 4.3Cr 56Cr 4.32Cr 4.23Cr 184.08Cr	91.41L 78.77L 73.85L 67.42L 1.27Cr 87Cr 1.27Cr 8.76Cr 3.42Cr 44Cr 3.43Cr 3.36Cr 146.23Cr

Company Profile

November 26, Inc., formerly BIOLASE, Inc., is not engaged in any business activities. The Company has no assets.

Employees

157

Sector

Date	Price	Change	Volume
27/26/27	$0.000000	-100.00%	1

Delayed Quote OTC Markets

Market Closed - OTC Markets 09:27:30 18/08/2026 pm IST			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-

27/25/27	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/25/19	EnVVeno Medical Names Jennifer Bright CFO	MT

27/25/27	MegaGen Implant Co., Ltd. acquired All Assets of BIOLASE, Inc from BIOLASE, Inc. (OTCPK:BIOL.Q).	CI
19/25/19	EnVVeno Medical Names Jennifer Bright CFO	MT
05/25/05	Motion for Asset Sale Approved for BIOLASE, Inc.	CI
25/25/25	Second Amended Combined Liquidation Plan & Disclosure Approved for BIOLASE, Inc.	CI
21/25/21	Second Amended Combined Liquidation Plan & Disclosure Statement Filed by BIOLASE, Inc.	CI
18/25/18	Motion for Exclusivity Period Extension Approved For BIOLASE, Inc.	CI
14/25/14	Motion for Asset Sale Filed by BIOLASE, Inc.	CI
29/25/29	First Motion for Exclusivity Period Extension Filed by BIOLASE, Inc.	CI
14/25/14	First Amended Disclosure Statement Approved on Interim Basis for BIOLASE, Inc.	CI
13/25/13	First Amended Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
08/25/08	Disclosure Statement Conditionally Approved for BIOLASE, Inc.	CI
23/24/23	Combined Liquidation Plan and Disclosure Statement Filed by BIOLASE, Inc.	CI
15/24/15	Motion for Asset Sale Approved for BIOLASE, Inc.	CI

01/24/01	Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating	MT
31/23/31	Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating	MT
20/23/20	Lake Street Assumes Biolase at Buy With $1.50 Price Target	MT
20/22/20	Lake Street Initiates Biolase at Buy, Sets Price Target at $12	MT

14/25/14	BIOLASE Showcases Breakthrough YSGG Laser Protocol for Predictable Periodontitis Treatment at AAP 2025	PR
08/24/08	Biolase: Q3 Earnings Snapshot	AQ
08/24/08	BIOLASE : Quarterly Report for Quarter Ending September 30, 2024 (Form 10-Q)	PU
02/24/02	BIOLASE : Voluntarily Initiates Chapter 11 Proceedings Form 8 K	PU
09/24/09	Biolase: Q2 Earnings Snapshot	AQ

Manager	Title	Age	Since
Gwang-Bum Park CEO	Chief Executive Officer	65	10/09/2025
Steven Sandor COO	Chief Operating Officer	46	06/07/2022
Samuel B. Low CTO	Chief Tech/Sci/R&D Officer	-	01/10/2016

Director	Title	Age	Since
Jonathan Lord CHM	Chairman	71	01/09/2017
Kathleen O'Loughlin BRD	Director/Board Member	75	16/08/2021
Martha Somerman BRD	Director/Board Member	-	16/08/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/09/23	Goldman Sachs & Co. LLC (Private Banking)	Other	Company	1,44,501	13.8444%
08/06/23	Jonathan Lord	Free	Chairman	7,21,154	2.3039%
08/06/23	Kathleen O'Loughlin	Free	Director	5,02,404	1.6050%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOLASE, INC.	0.00%	0.00%	-	-	36
CHURCHILL CAPITAL CORP XI	-3.05%	-4.12%	-	-	78Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	0.00%	0.00%	-	-	65Cr
CHURCHILL CAPITAL CORP XII	-0.28%	+1.03%	-	-	60Cr
CENTIEL AG	-1.01%	-9.29%	+282.51%	-77.63%	59Cr
BAIN CAPITAL GSS INVESTMENT CORP.	0.00%	0.00%	-	-	60Cr
CANTOR EQUITY PARTNERS IV, INC.	-0.05%	+0.19%	+2.07%	-	59Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	0.00%	-1.54%	-	-	57Cr
CHURCHILL CAPITAL CORP XIII	+0.47%	+0.86%	-	-	51Cr
Average	-0.44%	-1.43%	+142.29%	-77.63%	54.34Cr
Weighted average by Cap.	-0.60%	-1.72%	+142.26%	-77.63%